Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.

Article Details

Citation
Copy to clipboard

Coe MA, Lofwall MR, Walsh SL

Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.

J Addict Med. 2019 Mar/Apr;13(2):93-103. doi: 10.1097/ADM.0000000000000457.

PubMed ID
30531584 [ View in PubMed
]
Abstract

: Buprenorphine is an effective treatment for opioid use disorder. As a high-affinity, partial agonist for the mu-opioid receptor, buprenorphine suppresses opioid withdrawal and craving, reduces illicit opioid use, and blocks exogenous opioid effects including respiratory depression. Other pharmacologic benefits of buprenorphine are its superior safety profile compared with full opioid agonists and its long half-life that allows daily or less-than-daily dosing. New and innovative buprenorphine formulations, with pharmacokinetic profiles that differ from the original tablet formulation, continue to be developed. These include higher bioavailability transmucosal tablets and films and also 6-month implantable and monthly injectable products. This growing array of available formulations allows more choices for patients and increased opportunity for clinicians to individualize treatment; thus, it is important for buprenorphine prescribers to understand these differences.

DrugBank Data that Cites this Article

Drugs
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
BuprenorphineCytochrome P450 3A5ProteinHumans
Unknown
Substrate
Details